Study Title
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (BRAPP2) (NCT02298283)
Trial Description
This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).
This trial is sponsored by The Lymphoma Academic Research Organization (LYSARC) [1]
Study Data
- Condition: Hodgkin Lymphoma
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Cyclophosphamide (Cytoxan® ;Bristol-Myers Squibb Company
- Doxorubicin (Adriamycin®; Pfitzer, Inc.)
- Vincristine (Oncovin®; Hospira, Inc.)
- Bleomycin (Generic; Teva Parenteral Medicines, Inc.)
- Etoposide (Toposar®; Pfitzer, Inc.)
- Procarbazine (Matulane®; Sigma-Tau Pharmaceuticals)
- Prednisolone (Orapred®; Concordia Healthcare Corp.)
- G-CSF (Granulocyte-colony stimulating factor)
- Radiation: 30 Grays
- Drugs used in this trial
- Phase: II
- Estimated Enrollment: 40
- Start: December 2014
- Estimated Completion: February 2021
- Last verified: November 2014
Click here for an overview of other trials with brentuximab vedotion.
Study schematic
Click here to Return to Drug map
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
